A multicenter phase II trial for mogamulizumab conducted in Japan further identified an ORR of 34% in their cohort of PTCL treated with the anti-CCR4 antibody, but reported no significant correlation between CCR4 expression levels and response rates to mogamulizumab. This evidence concerns the gene CCR4 and mature T-cell and NK-cell non-Hodgkin lymphoma.